Title:
ANTI-EXCITOTOXIC SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS
Document Type and Number:
WIPO Patent Application WO/2005/107718
Kind Code:
A1
Abstract:
Biocompatible intraocular implants include an anti-excitotoxic agent and a polymer that is effective to facilitate release of the anti-excitotoxic agent into an eye for an extended period of time. The therapeutic agents like NMDA receptor anragonists like adamantine or memantine may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.
Inventors:
HUGHES PATRICK M (US)
SPADA LON T (US)
SUGIMOTO HIROSHI (JP)
BLANDA WENDY M (US)
CHANG JAMES N (US)
SPADA LON T (US)
SUGIMOTO HIROSHI (JP)
BLANDA WENDY M (US)
CHANG JAMES N (US)
Application Number:
PCT/US2005/015034
Publication Date:
November 17, 2005
Filing Date:
April 28, 2005
Export Citation:
Assignee:
ALLERGAN INC (US)
HUGHES PATRICK M (US)
SPADA LON T (US)
SUGIMOTO HIROSHI (JP)
BLANDA WENDY M (US)
CHANG JAMES N (US)
HUGHES PATRICK M (US)
SPADA LON T (US)
SUGIMOTO HIROSHI (JP)
BLANDA WENDY M (US)
CHANG JAMES N (US)
International Classes:
A61K9/00; A61K31/13; (IPC1-7): A61K9/22; A61K31/13
Domestic Patent References:
| WO2002043785A2 | 2002-06-06 |
Foreign References:
| EP0430539A2 | 1991-06-05 | |||
| US6380261B1 | 2002-04-30 | |||
| US20030175324A1 | 2003-09-18 | |||
| US6482854B1 | 2002-11-19 | |||
| US6369116B1 | 2002-04-09 | |||
| GB1372944A | 1974-11-06 | |||
| US6331313B1 | 2001-12-18 | |||
| US5677288A | 1997-10-14 |
Attorney, Agent or Firm:
Donovan, Stephen c/o Allergan (Inc. 2525 Dupont Driv, Irvine CA, US)
Download PDF: